CClinicalTrials.gg
TerminatedNCT05245864Updated Oct 9, 2024Results posted

Blood Flow Restriction Training in ACL Surgery

An interventional study of blood flow restriction and physical therapy standard of care in Anterior Cruciate Ligament Injuries, sponsored by University of Arkansas. Terminated at 1 site in United States. Open to participants aged 18 Years to 34 Years. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by University of Arkansas · Not applicable, Interventional, and Treatment

Why this study was terminated
Difficulty recruiting subjects; funding not renewed.
Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years to 34 Years
Sex
All
01

Study summary

This will be a randomized pilot study to determine the effectiveness of Personalized Blood Flow Restriction (PBFR) technique in conjunction with prescribed physical therapy (PT) in a cohort of anterior cruciate ligament (ACL) reconstruction subjects

Read the detailed description

This will be a randomized pilot study to determine the effectiveness of Personalized Blood Flow Restriction (PBFR) technique in conjunction with prescribed physical therapy (PT) in a cohort of anterior cruciate ligament (ACL) reconstruction subjects. Both groups of subjects will undergo unilateral ACL reconstruction at University of Arkansas for Medical Sciences (UAMS), followed by prescribed PT at the UAMS Orthopedic Clinic at Colonel Glenn.

Up to 25 subjects will be enrolled. Half are randomized to the BFR group with the other will perform PT without BFR.

Data collection will occur at four approximate occasions: pre-surgery, 8-weeks postop, 12-weeks postop, and 16-weeks postop.

02

Conditions studied

  • Anterior Cruciate Ligament Injuries
03

In context

Anterior Cruciate Ligament Injuries

512 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 164 are open to participants now.

This study's enrollment of 2 is below the median of 56 across 373 interventional studies indexed under Anterior Cruciate Ligament Injuries.

Browse Anterior Cruciate Ligament Injuries studies →

Lead sponsor

University of Arkansas is the lead sponsor of 391 studies on the registry; 39 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 34 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 34 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Men and women, ages 18-34 years.
  2. Scheduled to undergo elective ACL surgery at UAMS.
  3. Capable of providing informed consent.
  4. Willing to exercise with BFR.
  5. COVID-19 negative or asymptomatic.

Exclusion criteria

Exclusion Criteria:

  1. Any surgical indication other than ACL repair.
  2. Body mass index >40.
  3. Pregnant female.
  4. Neurological, musculoskeletal, or other disorder that would preclude them from completing the exercise training intervention and all performance tests.
  5. Hypertension as evidenced by systolic BP >150 at rest OR diastolic BP >85 at rest.
  6. Heart failure as evidenced by use of prescription diuretics.
  7. History of atrial fibrillation.
  8. Oxygen saturation \<95% on room air at rest.
  9. Any other medical condition that would interfere with testing or increase one's risk of complications during exercise.
  10. Currently receiving androgen (e.g., testosterone) or anabolic (e.g., GH, IGF-I) therapy.
  11. Compromised vascular circulation in the legs (e.g. peripheral vascular disease).
  12. History of deep vein thrombosis.
  13. Varicose veins in the legs.
  14. Known Sickle cell disease or trait.
  15. Unwilling to avoid using protein or amino-acid supplements during participation.
  16. Unwilling to avoid using BFR during prescribed post-operative physical therapy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    physical therapy with blood flow restriction

    Other: blood flow restriction

  • Other
    physical therapy without blood flow restriction

    Standard of care.

    Other: physical therapy standard of care

Interventions

  • Otherblood flow restriction

    Blood flow to the legs will be mostly restricted temporarily during physical therapy exercises for the initial several weeks of physical therapy.

  • Otherphysical therapy standard of care

    the current standard of care after surgery for ACL repair.

06

What researchers measure

Primary outcomes

  1. Maximal Voluntary Contraction

    Max torque produced in newton meter per second during an isometric contraction

    Time frame: 16-weeks post-surgery

  2. ACL Repair Range of Motion

    Measured at the knee, therefore, the degree to which the lower limb can move around knee joint in relation to the upper limb.

    Time frame: from enrollment to the end of treatment at 16 weeks

07

Results

Posted Oct 9, 2024

Participant flow

Participant flow — Overall Study
MilestonePhysical Therapy With Blood Flow RestrictionPhysical Therapy Without Blood Flow Restriction
Started11
Completed00
Not completed11
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryMaximal Voluntary Contraction

Max torque produced in newton meter per second during an isometric contraction

Time frame:
16-weeks post-surgery

No measurements were reported for this outcome.

PrimaryACL Repair Range of Motion

Measured at the knee, therefore, the degree to which the lower limb can move around knee joint in relation to the upper limb.

Time frame:
from enrollment to the end of treatment at 16 weeks

No measurements were reported for this outcome.

Adverse events

Collected over 20 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Physical Therapy With Blood Flow Restriction0/1 (0%)0/1 (0%)0/1 (0%)
Physical Therapy Without Blood Flow Restriction0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Physical Therapy With Blood Flow RestrictionPhysical Therapy Without Blood Flow RestrictionTotal
<=18 years000
Between 18 and 65 years112
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Physical Therapy With Blood Flow RestrictionPhysical Therapy Without Blood Flow RestrictionTotal
Female112
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Physical Therapy With Blood Flow RestrictionPhysical Therapy Without Blood Flow RestrictionTotal
Hispanic or Latino000
Not Hispanic or Latino112
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Physical Therapy With Blood Flow RestrictionPhysical Therapy Without Blood Flow RestrictionTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White011
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Physical Therapy With Blood Flow RestrictionPhysical Therapy Without Blood Flow RestrictionTotal
United States112
08

Study locations

1 site
  • UAMS Center on Aging
    Little Rock, Arkansas 72205, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Dec 3, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05245864
Lead sponsor
University of Arkansas
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Apr 18, 2022
Primary completion
Jan 30, 2023
Completion
Jan 30, 2023
Results posted
Oct 9, 2024
Last update
Oct 9, 2024

Study contacts

Arny A Ferrando, Ph.D.
principal investigator · University of Arkansas

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion